濮阳东方医院男科口碑很好(濮阳东方医院男科口碑高吗) (今日更新中)

The European Union is to propose ending twice-yearly clock changes after a large-scale public survey, European Commission President Jean-Claude Juncker said Friday.According to Juncker, more than 80% of EU citizens want to abolish daylight saving time and instead remain on the time used during summer instead.At the moment, each EU member state puts clocks forward one hour on the last Sunday of March and back again on the last Sunday in October."This debate about summertime, wintertime has been around for many years here," Juncker told German broadcaster ZDF."Many people are contributing to this debate. We did a survey, a public survey. Millions responded and think that in the future we should have summertime all year round. So that's what will happen.""The people want this; we will do this," he said.For any change to go into effect, legislation must be drafted and win approval from the 28 member nations and the European Parliament.One of the chief critics of daylight saving time has been Finland, which has one of the most northerly capital cities in the EU.Over 70,000 Finns signed a petition last October to urge the government to move away from daylight saving time.For Finland, the plan is also complicated by the fact it shares borders with non-EU states Russia, Belarus and Ukraine, all of which scrapped daylight saving time in 2011.Those in favor of the time change say the extra light in the morning during standard time and and additional evening light in summer can help prevent road accidents.The-CNN-Wire 1540

The Dow Jones Industrial Average sank more than 900 points on Wednesday , mirroring drops in European markets.The Dow Jones had its worst day since June 11. U.S. stocks recorded historic losses in February and March, fueled by shutdown measures to prevent the spread of COVID-19. However, since the shutdowns, U.S. markets have recovered to nearly the levels that were at prior to the pandemic.Despite stock recoveries, other important economic measuring sticks like unemployment remain historically high.Recent losses come as COVID-19 cases spike again across the country. Health experts warn that the U.S. is at a perilous point in the pandemic with rising hospital and death rates ahead of winter months. 715

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The founder of the Women's March is calling for the movement's current co-chairs to step down for allowing bigotry into their mission.Teresa Shook, a lawyer and educator who founded the Women's March movement, accused the group's current co-chairs -- Bob Bland, Tamika Mallory, Linda Sarsour and Carmen Perez -- of associating with bigoted outside groups and tarnishing the Women's March's initial goals in a post on her Facebook page Monday.The co-chairs "have steered the Movement away from its true course. I have waited, hoping they would right the ship," Shook wrote. "But they have not. In opposition to our Unity Principles, they have allowed anti-Semitism, anti-LBGTQIA sentiment and hateful, racist rhetoric to become a part of the platform by their refusal to separate themselves from groups that espouse these racist, hateful beliefs.""I call for the current Co-Chairs to step down and to let others lead who can restore faith in the Movement and its original intent," Shook added. "I stand in Solidarity with all the Sister March Organizations, to bring the Movement back to its authentic purpose."The Women's March leaders swiftly shot back, crediting Shook for "creating a Facebook event named the Million Women's March" and lambasting her for not working to support the movement's ongoing growth."Today, Teresa Shook weighed in, irresponsibly, as have other organizations attempting in this moment to take advantage of our growing pains to try and fracture our network," the Women's March wrote in a post on its Facebook page. "Groups that have benefited from our work but refuse to organize in accordance with our Unity Principles clearly have no interest in building the world our principles envision. They have not done the work to mobilize women from diverse backgrounds across the nation.""Our ongoing work speaks for itself. That's our focus, not armchair critiques from those who want to take credit for our labor," the statement continued.The 2019 Women's March is slated for January, two years after the initial march that followed President Donald Trump's inauguration, and inspired countless sister marches nationwide.Shook's critique comes following longstanding criticism of the group's association with Louis Farrakhan, the leader of the black nationalist group Nation of Islam, who has made numerous anti-Semitic and homophobic comments.Mallory and Perez have both posted photos on Instagram of themselves with Farrakhan praising the National of Islam leader, and Sarsour spoke at the Justice or Else rally headlined by Farrakhan in 2015. Mallory, an African-American leader of the Women's March and anti-gun violence activist, attended a large event in February where Farrakhan stated that "the powerful Jews are my enemy."Mallory declined to denounce Farrakhan after the event. The Women's March released a statement emphasizing that Farrakhan's statements were "not aligned with the Women's March Unity Principles" and that "our external silence has been because we are holding these conversations and are trying to intentionally break the cycles that pit our communities against each other."Sarsour said that following the shooting at the Tree of Life synagogue in Pittsburgh, critics suddenly called on the Women's March to denounce Farrakhan."There was nothing new that happened between Women's March and the Minister," Sarsour wrote in an online essay. "Folks decided to rehash 8 months ago."MPower Change, a Muslim organization that Sarsour co-founded, helped raise over 0,000 to cover the funeral expenses for the Tree of Life victims"This is not a letter in defense of Minister Farrakhan," she added. "He can do that for himself. We have been CRYSTAL CLEAR in BOTH of our statements that we REJECT antisemitism and all forms of racism. We have been CLEAR that Minister Farrakhan has said hateful and hurtful things and that he does not align with our Unity Principles of the Women's March that were created by Women of Color."A week before the Tree of Life shooting, Farrakhan made public anti-Semitic remarks, saying, "I'm not an anti-Semite. I'm anti-Termite." 4113

The British Broadcasting Corporation has reportedly opened an investigation into how journalist Martin Bashir secured Princess Diana's 1995 interview with the network after a shocking allegation aired during a two-part documentary on the British network ITV on Monday and Tuesday.According to USA Today, Bashir allegedly asked a graphic designer to create fake bank statements to persuade Princess Diana to talk to him on camera.According to the New York Times, doubts rose about how Bashir obtained the interview, but an earlier BBC internal investigation exonerated him.During the Nov. 20, 1995 interview, which aired on the BBC's program Panorama, the Princess spoke about how she desperately wanted her marriage to Prince Charles to work. She also spoke about the pressure from the media and her husband's infidelity that caused her to "escape" in binges of eating and vomiting, the Associated Press reported.According to the AP, an estimated 15 to 20 million viewers watched the Princess discuss her life, her children, and her estranged husband Prince Charles. 1074

来源：资阳报